Glucocorticoid Treatment in Addison's Disease
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01063569 |
Recruitment Status :
Completed
First Posted : February 5, 2010
Last Update Posted : March 20, 2013
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Addison's disease is a rare condition which in most cases is caused by autoimmune destruction of the adrenals, leading to deficiency of cortisol, aldosterone and adrenal androgens. Unrecognized the disease is life threatening, but with proper treatment patients can live near normal lives.
The conventional glucocorticoid replacement therapy renders the cortisol levels unphysiological, which may cause symptoms and long-term complications. Glucocorticoid replacement therapy is technically feasible by continuous subcutaneous hydrocortisone infusion (CSHI), and can mimic the normal diurnal cortisol rhythm. This study aims to further evaluate CSHI treatment in terms of metabolic effects, effects on health-related quality-of-life and sleep in an 8 months randomised open label clinical trial with crossover design.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Addison's Disease | Drug: Solu-Cortef (hydrocortisone) Drug: Cortef (hydrocortisone) | Phase 2 Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 33 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Glucocorticoid Treatment in Addison's Disease |
Study Start Date : | February 2010 |
Actual Primary Completion Date : | December 2012 |
Actual Study Completion Date : | December 2012 |

Arm | Intervention/treatment |
---|---|
Active Comparator: Oral hydrocortisone |
Drug: Cortef (hydrocortisone)
Oral treatment 3 times a day. Weight adjusted doses.
Other Name: Cortef 5 mg |
Experimental: Continous subcutaneous hydrocortisone infusion |
Drug: Solu-Cortef (hydrocortisone)
Continuous Subcutaneous Hydrocortisone infusion via insulin pump. Doses adjusted to body surface area.
Other Name: Solu-Cortef |
- Morning (08-09) plasma ACTH [ Time Frame: Time 0, months 2, 3, 5, 7 and 8 ]
- Health-Related Quality of Life; evaluated by SF-36 vitality scores and AddiQoL scores [ Time Frame: At time 0 and months 2,3,5,7 and 8 ]
- Sleep; evaluated by Pittsburgh Sleep Quality Index (PSQI), and 7-days' Actigraph registration combined with self-reported sleep diary [ Time Frame: PSQI: 0 and months 2,3,5,7 and 8; Actigraph/sleep diary: months 2 and 7 ]
- 24h cortisol profiles in serum and saliva [ Time Frame: months 2 and 7 ]
- S-glucose, 24 h profile [ Time Frame: months 2 and 7 ]
- Insulin sensitivity assessed by euglycemic clamp [ Time Frame: Months 2 and 7 ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 70 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients with verified Addison's disease on stable treatment.
Exclusion Criteria:
- Insulin treated Diabetes Mellitus, cardiovascular disease,malignant disease, pregnancy.
- Treatment with glucocorticoids or drugs that interfere with cortisol metabolism (antiepileptics, rifampicin, St. John's wart).

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01063569
Norway | |
Haukeland University Hospital | |
Bergen, Norway, 5021 | |
Sweden | |
Karolinska Institutet | |
Stockholm, Sweden | |
Uppsala University | |
Uppsala, Sweden |
Principal Investigator: | Kristian Løvås, MD,PhD | Haukeland University Hospital |
Responsible Party: | Haukeland University Hospital |
ClinicalTrials.gov Identifier: | NCT01063569 |
Other Study ID Numbers: |
3.2007.2343 2009-010917-61 ( EudraCT Number ) |
First Posted: | February 5, 2010 Key Record Dates |
Last Update Posted: | March 20, 2013 |
Last Verified: | March 2013 |
Addison's disease Glucocorticoid treatment Continuous subcutaneous hydrocortisone infusion |
CSHI Quality of Life Sleep |
Addison Disease Adrenal Insufficiency Adrenal Gland Diseases Endocrine System Diseases Autoimmune Diseases Immune System Diseases |
Hydrocortisone Hydrocortisone 17-butyrate 21-propionate Hydrocortisone acetate Hydrocortisone hemisuccinate Anti-Inflammatory Agents |